Literature DB >> 843872

Cushing's disease: failure of treatment with cyproheptadine.

J Allgrove, P Husband, C G Brook.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843872      PMCID: PMC1605565          DOI: 10.1136/bmj.1.6062.686-a

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  2 in total

1.  Inhibition of hypoglycemia-induced cortisol secretion by the serotonin antagonist cyproheptadine.

Authors:  J W Plonk; C H Bivens; J M Feldman
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

2.  Cyproheptadine-induced remission of Cushing's disease.

Authors:  D T Krieger; L Amorosa; F Linick
Journal:  N Engl J Med       Date:  1975-10-30       Impact factor: 91.245

  2 in total
  5 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma.

Authors:  T C Ooi; Y Twum-Barima
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

3.  Cushing's disease presenting with growth failure: clinical remission during cyproheptadine therapy.

Authors:  D B Grant; S M Atherden
Journal:  Arch Dis Child       Date:  1979-06       Impact factor: 3.791

4.  Cyproheptadine treatment in Cushing's disease.

Authors:  R Tanakol; F Alagöl; H Azizlerli; O Sandalci; T Terzioğlu; F Berker
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

5.  Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.